Carl Fier, MD
Interventional Cardiology · Manchester, NHNPI 1841268224
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $2,289 of the $3,001 with a category attached, or 76.3%. 16 manufacturers reported payments, led by Abbott at 43.4% of the total. Reporting peaked in 2019 at $1,729 and has fallen 98.6% since, to $25 in 2025. That places this record below the midpoint for interventional cardiology clinicians in NH, where the typical reported total is $5,309.
Across 87 payments — averaging $34.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$1K
- Johnson & Johnson$434
- Boston Scientific$348
- Abiomed$192
- Actelion Pharmaceuticals US, Inc.$132
- Edwards Lifesciences$110
- plus $481 from 10 others
What the payments were for
- Travel & lodging$61721%
- Food & beverage$2,28976%
- Education$953%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 14 | $1,304 |
| Johnson & Johnson | 31 | $434 |
| Boston Scientific | 7 | $348 |
| Abiomed | 3 | $192 |
| Actelion Pharmaceuticals US, Inc. | 9 | $132 |
| Edwards Lifesciences | 2 | $110 |
| GE HealthCare | 1 | $101 |
| AstraZeneca | 5 | $95 |
| Medtronic | 3 | $89 |
| Novartis | 4 | $63 |
| Boehringer Ingelheim | 1 | $32 |
| E.r. Squibb & Sons, L.L.C. | 2 | $25 |
| Kowa Pharmaceuticals America, Inc. | 2 | $25 |
| Pfizer | 1 | $19 |
| Terumo Medical Corporation | 1 | $15 |
| Bayer | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,001 in reported general payments places this provider in the 35th percentile of 26 interventional cardiology providers in New Hampshire.
See all interventional cardiology providers in New Hampshire →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OpsumitMacitentan | 61 | $740,559 |
| EliquisApixaban | 228 | $284,280 |
| XareltoRivaroxaban | 178 | $219,923 |
| Repatha SureclickEvolocumab | 71 | $54,077 |
| MultaqDronedarone Hcl | 16 | $24,686 |
| EntrestoSacubitril/Valsartan | 19 | $23,968 |
| FarxigaDapagliflozin Propanediol | 20 | $12,021 |
| Flecainide Acetate | 148 | $11,127 |
| Praluent PenAlirocumab | 16 | $8,787 |
| Metoprolol Succinate | 470 | $5,870 |
| Diltiazem 24hr Er (Cd)Diltiazem Hcl | 112 | $3,394 |
| Atorvastatin Calcium | 284 | $2,998 |
| Sildenafil Citrate | 12 | $2,803 |
| Rosuvastatin Calcium | 139 | $2,179 |
| Isosorbide Mononitrate ErIsosorbide Mononitrate | 96 | $1,578 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Actelion Pharmaceuticals US, Inc.Opsumit | $132 | $740,55961 claims |
| PfizerEliquis | $19 | $284,280228 claims |
| Johnson & JohnsonXarelto | $434 | $219,923178 claims |
| NovartisEntresto | $63 | $23,96819 claims |
| AstraZenecaFarxiga | $95 | $12,02120 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 26 interventional cardiology providers in New Hampshire.
Other interventional cardiology in Manchester
- Xiaoyu Yang-GiulianoManchester$18K
- Johny KuttabManchester$5K
- Shahab MoossaviConcord$36K
- Nitish SharmaDover$23K
- Rodrigo Mendirichaga MaganaDover$21K
- Hannah ChaudryLebanon$20K
- Eric RothsteinLebanon$20K
- James DevriesLebanon$19K
- Lazaro DiazExeter$15K
- Aaron KaplanLebanon$13K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.